Type Whole antibody Target PD-1 CAS Number 1036730-42-3 | ATC code none ChemSpider none | |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Clinical trials
It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma. A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.
References
Pidilizumab Wikipedia(Text) CC BY-SA